TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Incretins in Bone Remodeling in Humans

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* healthy women and men~Exclusion Criteria:~* known osteoporosis~* osteoporotic fracture~* tobacco~* alcohol : \> 2 glasses/day~* type 1 and type 2 diabetes~* BMI \< 19kg/m² or \> 30kg/m²~* heart failure, kidney failure~* cancer~* bariatric surgery~* graft~* cirrhosis~* use in the past year : bisphosphonate, denosumab, raloxifene, teriparatide, oral or IV glucocorticoid during 3 months or more

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (all required):~* Systolic blood pressure (SBP) \>/= 140 and/or diastolic blood pressure (DBP) \>/= 90 (untreated hypertension cases); or SBP\>/=130 and/or DBP\>/=80 (treated hypertension cases)~* Patients with coronary artery disease (more than 50% stenosis on coronary angiography \[CAG\], coronary computed tomography \[CT\] or coronary magnetic resonance angiography \[MRA\]; coronary spasm; or history of percutaneous coronary intervention \[PCI\]);Unstable angina patient~* Creatinine clearance between 30.0 and 89.9 ml/min~Exclusion Criteria (at least one of following):~* Reduced left ventricular (LV) function (ejection fraction \[EF\] equal to or less than 40%)~* Hyperpotassemia (serum potassium equal to or more than 5.5 mEq/l)~* Rapid progressive glomerular nephritis~* Nephrotic syndrome~* Renal artery stenosis~* Uncontrolled diabetes (HbA1c equal to or more than 9.0%)~* History of allergy to valsartan~* Pregnant women

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Valsartan 40mg (Type: ACTIVE_COMPARATOR): Standard Dose valsartan
- Valsartan 160mg (Type: ACTIVE_COMPARATOR): High Dose valsartan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Delivra-Celecoxib 8% Cream and Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females age 30 to 75.~2. Written informed consent~3. Patients with primary osteoarthritis (with radiological evidence) of the knees who have been prescribed Del-Cel.~4. On stable pain therapy with an oral or topical NSAID or acetaminophen.~5. Able to read and understand English to answer pain assessment questions independently.~6. Willing and able to fulfill the requirements of the study, including complete scheduled follow-up phone visits.~Exclusion Criteria:~1. Secondary OA of the study knee~2. History of pseudo gout or inflammatory flare-ups~3. Major surgery or previous damage to the study knee at any time, or minor knee surgery to the study knee within 1 year of visit 1.~4. Requires oral or intra-muscular corticosteroids or received an intra articular corticosteroid injection into the study knee within the past 90 days of visit 1, or into any other joint within the past 30 days of visit 1, or currently applying topical corticosteroids onto the study knee.~5. Received intra-articular viscosupplementation (eg, hylan G-F 20 \[Synvisc®\]) in the study knee in the past 6 months of visit 1.~6. On prior stable therapy (ie, more than 3 days per week for the previous month) with an opioid analgesic prior to the screening visit will be excluded.~7. Previously withdrawn from this study~8. History of fibromyalgia~9. Other painful or disabling conditions affecting the knee or leg, or disabling condition of the hands (used to apply the study drug)~10. Skin disorder with current involvement on the hands (used to apply the study drug) or the knee(s) (application site)~11. Referred to an orthopedic surgeon for consideration of, or been advised to have, knee replacement or knee reconstruction surgery~12. Radiologic evidence of OA of the knee advanced to the point that all cartilage has been eroded (ie, bone on bone)~13. Recently started using a cane within the past 30 days prior to visit 1.~14. History of chronic headaches, or other condition, that may require more than occasional use of rescue medication, e.g.: acetaminophen.~Subjects that do not meet all the enrollment criteria may not be enrolled. Any violations of these criteria must be reported in accordance with IRB Policies and Procedures.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Two Drugs (Propofol and Nitroglycerin as a Hypotensive Agents During Endoscopic Sinus Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ASA I and II diagnosed for chronic sinusitis~* Age range between 18-60 years, undergoing elective FESS without septoplasty under general anesthesia.~Exclusion Criteria:~* included any patient with bleeding disorder, on anticoagulant therapy~* renal, hepatic or cardiac dysfunction~* history of cerebrovascular stroke~* peripheral vascular diseases~* allergic to any of the study drugs~* hypertension~* morbid obesity and~* recurrent endoscopic sinus surgeries

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- propofol group (Type: ACTIVE_COMPARATOR): propofol group will receive propofol infusion
- nitroglycerin group (Type: ACTIVE_COMPARATOR): will receive nitroglycerin infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, over the age of 18 years~* Diagnosis of moderate-to-severe active early rheumatoid arthritis (RA) of less than 2 years duration~* DAS28 \>3.2~* Swollen joint count (SJC) \>/=6 (66 joint count), and tender joint count (TJC) \>/=6 (68 joint count)~* Patients who have received DMARDs (including methotrexate) for 3-7 months~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline~* Rheumatic autoimmune disease other than rheumatoid arthritis (secondary Sjögrens syndrome or nodulosis with RA is permitted)~* Functional class III or IV as defined by ACR Classification of Functional Status in Rheumatoid Arthritis~* Prior history of or current inflammatory joint disease other than RA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed hematologic malignancy that has failed standard therapy or for which no standard therapy exists, including, but not limited to, the following: Acute lymphocytic leukemia Acute myelogenous leukemia Chronic lymphocytic leukemia Chronic myelogenous leukemia Multiple myeloma Non-Hodgkin's lymphoma Hodgkin's disease No history of CNS disease, including carcinomatous meningitis~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: CTC 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin: Groups 1-4: Less than 1.5 times upper limit of normal (ULN) Group 5: 1.5-4 times ULN Renal: Creatinine clearance: Groups 1 and 5: Greater than 50 mL/min Group 2: 30-50 mL/min Group 3: Less than 30 mL/min Group 4: Less than 30 mL/min, requiring dialysis Neurologic: No history of grade 2 peripheral neuropathy No history of seizure disorder No history of neurologic dysfunction Other: Not pregnant or nursing Fertile patients must use effective contraception HIV negative~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy (e.g., interferon, monoclonal antibodies) No concurrent interleukin-11 for treatment or prevention of thrombocytopenia No concurrent prophylactic colony stimulating factors Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for melphalan, carmustine, or mitomycin) At least 72 hours since prior hydroxyurea No prior 506U78 No other concurrent chemotherapy Endocrine therapy: At least 72 hours since prior glucocorticoids Concurrent continuation of steroids for adrenal failure allowed No concurrent hormones except for nondisease related conditions (e.g., insulin for diabetes) No concurrent dexamethasone or other steroidal antiemetics Radiotherapy: At least 4 weeks since prior radiotherapy No concurrent palliative radiotherapy No concurrent whole brain irradiation for documented CNS disease Surgery: Not specified Other: At least 72 hours since prior aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Compound 506U78 (Type: EXPERIMENTAL): Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dedicated Breast CT for Diagnosis of Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women age 50 or older~Initial schema:~- Women who are scheduled to undergo a diagnostic work-up following an abnormal screening mammogram with the suspicious finding NOT located in the axillary tail of the breast This initial inclusion criterion will be used until 85 subjects that result in a Breast Imaging Reporting and Data System (BI-RADS) 1 or 2 after clinical diagnostic work-up are recruited and imaged.~Subsequent schema:~- Women who underwent diagnostic work-up following an abnormal screening mammogram and were assigned a BI-RADS 4 or 5 due to soft tissue lesions (total 120 patients when combined with those from the initial schema), or due to microcalcifications (total 120 patients when combined with those from the initial schema) with the suspicious finding NOT located in the axillary tail of the breast~Each patient can only enroll once in the study.~Exclusion Criteria:~* Women who do not meet the inclusion criteria as described above~* Women with suspected or confirmed pregnancy~* Women who have had bilateral mastectomy~* Women whose suspicious lesion is located in the axillary tail~* Women with prior breast cancer or breast biopsy in the recalled breast in the last 12 months~* Women who are breastfeeding~* Women who are very frail and unable to cooperate~* Women who cannot give informed consent~* Male subjects

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven dx of recurrent or metastatic breast cancer~* Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer. Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease. Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease.~* Unidimensionally measurable dz (by RECIST)~* At least 18 yrs of age~* SWOG PS 0-2~* AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0~* Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln~* Creatinine less than or equal to 2.0~* Fully recovered from acute toxicities secondary to prior tx~* Signed informed consent (including HIPAA authorization)~* Peripheral neuropathy grade 0-1~Exclusion Criteria~* Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \>12 mos prior to enrollment.~* Underlying medical, psychiatric, or social conditions that would preclude patient from receiving tx~* Peripheral neuropathy greater than or equal to Gr 2~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Prophylaxis Immunologic Challenge (EPIC) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with severe and moderately severe hemophilia A (FVIII ≤ 2%)~* Participants \< 1 year of age~* Participants must have ≤ 3 exposure days (EDs) to any FVIII concentrate or FVIII-containing product used for treatment of minor bleeds (bleeds requiring no more than 2 infusions per event), or for preventative or precautionary infusions following possible injury~* Participants with prior circumcision are allowed to enroll only if bleeding issues related to circumcision were the cause for the original diagnosis of hemophilia A and no more than 2 EDs of FVIII treatment were required~* Adequate venous access (without need for central venous access device (CVAD)-placement) as determined by the physician~* Written informed consent from legally authorized representative(s)~Exclusion Criteria:~* Life-threatening conditions (intracranial hemorrhage, severe trauma) or requirement for surgery at the time of enrollment~* Evidence of inhibitor ≥ 0.6 Bethesda Unit (BU) in Nijmegen-modified Bethesda Assay at study start (samples may be retested using lupus-insensitive inhibitor tests to reduce the number of false positive inhibitor test results)~* Inherited or acquired hemostatic defect other than hemophilia A~* Any clinically significant, chronic disease other than hemophilia A~* Known hypersensitivity to ADVATE or any of its constituents~* Any planned elective surgery that cannot be postponed until after the first 20 EDs~* Participation in the Hemophilia Inhibitor Previously Untreated Patient Study~* Application of red blood cell, platelet, or leukocyte concentrates, or plasma~* Administration of any medication affecting coagulation or platelet function~* Systemic administration of any immunomodulatory drug (eg, chemotherapy, intravenous glucocorticoids)~* Participation in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or during the course of this study

- Gender: MALE
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- ADVATE - Prophylactic Regimen (Type: EXPERIMENTAL): Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Automated Mobile Contingency Management for Smoking Cessation: A Pilot RCT (SCC PREVAILgo)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
1. annual Household income of \< 200% of the federal poverty threshold (i.e., low-income) given household size~2. earn a score ≥ 4 on the REALM indicating \> 6th grade English literacy level~3. are willing to quit smoking 7 days after enrollment~4. are ≥ 18 years of age~5. currently smoke ≥ 5 cigarettes per day~6. have a CO level of \> 6 ppm~7. have no contraindications for NRT~8. willingness to complete an identity check (i.e., video conference call or provide a photo ID).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Mobile Contingency Management (Type: EXPERIMENTAL): None
- Standard Care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Hospital In-Patient Insulin Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type II diabetes~* Blood glucose \> 17mmols~Exclusion Criteria:~* Type I diabetes~* Hyperosmolar non-ketotic coma (HONK)~* Diabetic ketoacidosis (DKA)~* Myocardial infarction (MI)~* Vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to give informed consent~* Male or female patient whose age is \> 18 years of age~* Histological documented Stage IV malignant melanoma (American Joint Committee on Cancer (AJCC) sixth edition)~* Pathology report from tumor specimen verifying melanoma diagnosis~* Free of infection~* Hemoglobin\> 9.0 grams per deciliter (gm/dL), White Blood Cells (WBC) \>3000/ cubic millimeters (mm3), platelets\> 100,000mm3~* Liver function test that are less than 2 times the upper limit of normal of the reference range for the testing laboratory~* Adequate cardiac function-any evidence of ischemic heart disease demonstrated by history, physical, or EKG will require referral to a cardiologist for evaluation and clearance prior to protocol therapy~* No immunotherapy within the past 3 months~* A minimum of 4 doses of lot-released, autologus Melaxin (1.0 million dendritomas)~Exclusion Criteria:~* Other malignancies in the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix~* Has received any immunosuppressive agent within 30 days prior to treat~* Creatinine\> 2.5 milligrams per deciliter (mg/dL) or currently on dialysis~* Positive serum pregnancy test, breast-feeding,or planning to conceive or father or father a child in the period surrounding the study as described in the informed consent.~* Women of childbearing potential who cannot follow the directions for birth control~* Eastern Cooperative Oncology Group (ECOG) performance status greater than 3~* Positive Rdonr panel (Human Immunodeficiency virus (HIV) 1, 2; Human T-lymphotropic virus (HTLV-1,2); Hepatitis B and C)~* History of a seizure disorder~* Brain metastases that have progressed within the last 6 months~* No measurable disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melaxin and BCG (Type: EXPERIMENTAL): Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues